Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients

Indolfi, 2019, Hepatitis C virus infection in children and adolescents, Lancet Gastroenterol. Hepatol, 4, 477, 10.1016/S2468-1253(19)30046-9 Hepatitis, 2019 Daher, 2019, Treatment of chronic HCV infection in patients with thalassemia, Clin Liver Dis, 14, 199, 10.1002/cld.853 Nguyen, 2019, Cost effectiveness of early treatment with direct-acting antiviral therapy in adolescent patients with hepatitis C virus infection, J Pediatr, 207, 90, 10.1016/j.jpeds.2018.12.012 2017, FDA approves two hepatitis C drugs for pediatric patients 2017, HCV in childern 2016 Balistreri, 2017, The safety and effectiveness of ledipasvir− sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection, Hepatology, 66, 371, 10.1002/hep.28995 El-Khayat, 2018, The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience, Aliment Pharmacol Ther, 47, 838, 10.1111/apt.14502 El-Araby, 2019, Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9–12 years) and adolescents, Hepatol Int, 13, 706, 10.1007/s12072-019-09985-w 2019 Smolders, 2019, Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations: a 2019 update, Clin Pharmacokinet, 58, 1237, 10.1007/s40262-019-00774-0 El-Karaksy, 2018, Sustained viral response in Genotype 4 chronic Hepatitis C virus–infected children and adolescents treated with sofosbuvir/ledipasvir, J Pediatr Gastroenterol Nutr, 67, 626, 10.1097/MPG.0000000000002101 Nagral, 2019, Treatment of chronic hepatitis C infection with direct acting antivirals in adolescents with thalassemia major, Indian J Pediatr, 86, 148, 10.1007/s12098-018-2752-7 Rower, 2015, Validation and application of a liquid chromatography-tandem mass spectrometry method to determine the concentrations of sofosbuvir anabolites in cells, Antimicrob Agents Chemother, 59, 7671, 10.1128/AAC.01693-15 Kirby, 2015, Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir, Clin Pharmacokinet, 54, 677, 10.1007/s40262-015-0261-7 2014 Kremastinos, 2010, β-thalassemia cardiomyopathy: history, present considerations, and future perspectives, Circ Heart Fail, 3, 451, 10.1161/CIRCHEARTFAILURE.109.913863 Malik, 2009, Complications in transfusion–dependent patients of ß-thalassemia major: a review, Pak J Med Sci, 25, 678 Wang, 2012, Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies, J Clin Pharmacol, 52, 1601, 10.1177/0091270011422812 2015 Abdallah, 2017, Development a validated highly sensitive LC–MS/MS method for simultaneous quantification of Ledipasvir, sofosbuvir and its major metabolite GS-331007 in human plasma: Application to a human pharmacokinetic study, J Pharm Biomed Anal, 143, 305, 10.1016/j.jpba.2017.06.005 Goksuluk, 2016, easyROC: An Interactive Web-tool for ROC Curve Analysis Using R Language Environment, R J, 8, 213, 10.32614/RJ-2016-042 2017 2019, Description of column-types used to define responses-censoring 2019 2020 2019, FDA approves first treatment for all genotypes of hepatitis C in pediatric patients Abdella, 2018, Blood transfusion and hepatitis: what does it take to prevent new infections?, East. Mediterr. Health J., 24, 595, 10.26719/2018.24.6.595 Musharraf, 2017, β-Thalassemia patients revealed a significant change of untargeted metabolites in comparison to healthy individuals, Sci Rep, 1 Pennell, 2013, Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association, Circulation, 128, 281, 10.1161/CIR.0b013e31829b2be6 Eipel, 2010, Regulation of hepatic blood flow: the hepatic arterial buffer response revisited, World J Gastroenterol, 16, 6046, 10.3748/wjg.v16.i48.6046 Demosthenous, 2018, β-Thalassemia and renal complications. A narrative review of pathophysiologic mechanisms, Integr Mol Med, 5, 1, 10.15761/IMM.1000340 Cuenca-Lopez, 2017, Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C, Expert Opin Drug Metab Toxicol, 13, 105, 10.1080/17425255.2017.1255725 Poustchi, 2013, Transient elastography in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis, Hepatol. Res., 43, 1276, 10.1111/hepr.12088 Tsoris, 2019, Use of the Child Pugh score in liver disease Mangia, 2017, Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection, Aliment Pharmacol Ther, 46, 424, 10.1111/apt.14197 2017 2015 Ahmed, 2019, Pharmacokinetics profile of serum and cellular sofosbuvir along with its concentration effect analysis in HCV patients receiving sofosbuvir and ribavirin, Pak J Med Sci, 32 Jin, 2015, Population pharmacokinetic modeling of sofosbuvir, an NS5B polymerase inhibitor, and its metabolites in patients with Hepatitis C virus infection-abstract 3323 Jansen, 2017, Identification of predictors for treatment failure in hepatitis C virus patients treated with ledipasvir and sofosbuvir, Ann Pharmacother, 51, 543, 10.1177/1060028017693348 Lawitz, 2012, A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C, J Hepatol, 57, 24, 10.1016/j.jhep.2011.12.029 Afdhal, 2014, Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection, N Engl J Med, 370, 1889, 10.1056/NEJMoa1402454 Shiha, 2019, Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt, Gut, 68, 721, 10.1136/gutjnl-2017-315906 Swifee, 2020, Comparative study between the efficacy of using sofosbuvir/daclatasvir and sofosbuvir/ledipasvir in treatment of hepatitis C virus in Egypt, J. Curr. Med. Res. Pract., 5, 212